Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.

about

Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.

Item

http://www.wikidata.org/entity/Q47315442

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@en

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@nl

type

Item

label

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@en

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@nl

prefLabel

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@en

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@nl

P1476

Point-Counterpoint: Piperacill ...... with ESBL-positive organisms.

@en

P2093

Audrey Schuetz

http://www.w3.org/2001/XMLSchema#string

Pranita D Tamma

http://www.w3.org/2001/XMLSchema#string

Sergio Reyes Salcedo

http://www.w3.org/2001/XMLSchema#string

P2860

A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae.

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.

Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia

P31

scholarly article

review article

P356

10.1128/JCM.01917-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29237787

http://www.w3.org/2001/XMLSchema#string

P932

5824049

http://www.w3.org/2001/XMLSchema#string